《bioRxiv,2月21日,Potential T-cell and B-cell Epitopes of 2019-nCoV》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-02-22
  • Potential T-cell and B-cell Epitopes of 2019-nCoV

    Ethan Fast, Binbin Chen

    doi: https://doi.org/10.1101/2020.02.19.955484

    Abstract

    As of Feb 16th 2020, 2019-nCoV has infected more than 51,857 people across 26 countries and claimed 1666 lives. 2019-nCoV is a novel form of coronavirus that causes COVID-19 and has high similarity with SARS-CoV. No approved vaccine yet exists for 2019-nCoV or any form of coronavirus. Here we use computational tools from structural biology and machine learning to identify 2019-nCoV T-cell and B-cell epitopes based on viral protein antigen presentation and antibody binding properties. These epitopes can be used to develop more effective vaccines and identify neutralizing antibodies. We identified 405 viral peptides with good antigen presentation scores for both human MHC-I and MHC-II alleles, and two potential neutralizing B-cell epitopes near the 2019-nCoV spike protein receptor binding domain (440-460 and 494-506). Analyzing mutation profiles of 68 viral genomes from four continents, we identified 96 coding-change mutations. These mutations are more likely to occur in regions with good MHC-I presentation scores (p=0.02). No mutations are present near the spike protein receptor binding domain. We validated our computational pipeline with SARS-CoV experimental data.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.biorxiv.org/content/10.1101/2020.02.19.955484v1
相关报告
  • 《JMV,2月5日,Immunoinformatics-aided Identification of T Cell and B Cell Epitopes in the Surface Glycoprotein of 2019-nCoV》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-06
    • Immunoinformatics-aided Identification of T Cell and B Cell Epitopes in the Surface Glycoprotein of 2019-nCoV Vargab Baruah, Sujoy Bose PMID: 32022276 DOI: 10.1002/jmv.25698 Abstract The 2019 novel coronavirus (2019-nCoV) outbreak has caused a large number of deaths with thousands of confirmed cases worldwide, especially in East Asia. This study took an immunoinformatics approach to identify significant cytotoxic T lymphocyte (CTL) and B cell epitopes in the 2019-nCoV surface glycoprotein. Also, interactions between identified CTL epitopes and their corresponding MHC class I supertype representatives prevalent in China were studied by molecular dynamics simulations. We identified five CTL epitopes, three sequential B cell epitopes and five discontinuous B cell epitopes in the viral surface glycoprotein. Also, during simulations, the CTL epitopes were observed to be binding MHC class I peptide-binding grooves via multiple contacts, with continuous hydrogen bonds and salt bridge anchors, indicating their potential in generating immune responses. Some of these identified epitopes can be potential candidates for development of 2019-nCoV vaccines. This article is protected by copyright. All rights reserved.
  • 《2月21日_2019-nCoV的潜在T细胞和B细胞表位》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-02-22
    • 信息名称:2019-nCoV的潜在T细胞和B细胞表位 1.时间:2020年2月21日 2.机构或团队:斯坦福大学 3.事件概要: 斯坦福大学的科研人员在bioRxiv预印版平台发表论文“Potential T-cell and B-cell Epitopes of 2019-nCoV”,使用来自结构生物学和机器学习的计算工具,基于病毒蛋白抗原呈递和抗体结合特性来识别2019-nCoV T细胞和B细胞表位,为开发有效疫苗和鉴定中和抗体提供支撑。 文章指出,截至2020年2月16日,2019-nCoV已感染26个国家的51,857多人,并夺走了1666条生命。2019-nCoV是冠状病毒的一种新型形式,可导致COVID-19并与SARS-CoV高度相似,目前尚无批准用于2019-nCoV或任何形式冠状病毒的疫苗。文章中,科研人员使用来自结构生物学和机器学习的计算工具,基于病毒蛋白抗原呈递和抗体结合特性来识别2019-nCoV T细胞和B细胞表位,这些表位可用于开发更有效的疫苗并鉴定中和抗体。科研人员确定了405个具有良好抗原呈递得分的病毒肽,它们分别针对人类MHC-I和MHC-II等位基因,以及2019-nCoV刺突蛋白受体结合域附近的两个潜在中和性B细胞表位(440-460和494-506)。通过分析来自四大洲的68个病毒基因组的突变图谱,科研人员确定了96个编码变化突变,这些突变更可能发生在具有良好MHC-1表现评分的区域(p = 0.02),在刺突蛋白受体结合域附近没有突变存在。科研人员使用SARS-CoV实验数据验证了计算方法。 *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用. 4.附件: 原文链接: https://www.biorxiv.org/content/10.1101/2020.02.19.955484v1.full.pdf